Bayer moves closer to H&R sale
This article was originally published in The Rose Sheet
Executive Summary
Fragrance and flavors supply business Haarmann & Reimer is expected to sell above current market expectations of $1.33 bil. (€1=$.88), Bayer says. Many competitors in the chemical industry have expressed interest in acquiring the division, Bayer adds. Among companies reportedly planning to bid for H&R are Swiss fragrance supplier Givaudan and German chemicals business Degussa. Although neither company would confirm their intentions, both say they are interested in future acquisitions. Bayer announced plans to sell Haarmann & Reimer in December as one of three divisions the company is shedding to focus on "core" businesses (11"The Rose Sheet" Dec. 10, 2001, p. 6)...
You may also be interested in...
Haarman & Reimer Eyes Improved Market Position Through Pending Sale
Bayer Corp. aims to divest fragrance and flavor manufacturer Haarman & Reimer by the end of 2002, the German company announced Dec. 6
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.